Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03756051 · ClinicalTrials.gov registry record
Harms of Hepatocellular Carcinoma Surveillance
A clinical trial, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- 2,871
- Enrollment target
NCT03756051 is a clinical trial that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 2,871 participants.
The verdict
NCT03756051 has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- 2,871 participants
- Enrollment target
Study Summary
This study leverage a multi-center randomized controlled trial assessing screening-related benefits (i.e. early tumor detection, treatment eligibility, and overall survival) among a racially and socioeconomically diverse population of patients with cirrhosis. However, the randomized controlled trial was not budgeted to assess hepatocellular carcinoma screening-related harms. The goal of this study is to quantify physical, financial, and psychosocial harms across three healthcare settings.
Interventions
- OTHER Prospective Longitudinal Data
- OTHER Surveys and Semi-structured Interviews
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,871 participants |
| Start Date | 2018-04-01 |
| Est. Completion | 2022-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03756051
The ClinicalTrials.gov registry entry for NCT03756051 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,871 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prospective Longitudinal Data is the first listed.
NCT03756051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03756051 about?
NCT03756051 is a clinical study titled "Harms of Hepatocellular Carcinoma Surveillance". This study leverage a multi-center randomized controlled trial assessing screening-related benefits (i.e. early tumor detection, treatment eligibility, and overall survival) among a racially and socioeconomically diverse population of patients with cirrhosis. However, the randomized controlled trial...
What is the current status of trial NCT03756051?
This trial is currently completed. The enrollment target is 2,871 participants. The study started on 2018-04-01. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT03756051?
The interventions under investigation include: Prospective Longitudinal Data (OTHER), Surveys and Semi-structured Interviews (OTHER).
Who is sponsoring clinical trial NCT03756051?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.